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Abstract
Equine recurrent uveitis (ERU) is an immune‐mediated disease causing repeated or 
persistent inflammatory episodes which can lead to blindness. Currently, there is no 
cure for horses with this disease. Mesenchymal stem cells (MSCs) are effective at re-
ducing immune cell activation in vitro in many species, making them a potential ther-
apeutic option for ERU. The objectives of this study were to define the lymphocyte 
phenotype of horses with ERU and to determine how MSCs alter T‐cell phenotype 
in vitro. Whole blood was taken from 7 horses with ERU and 10 healthy horses and 
peripheral blood mononuclear cells were isolated. The markers CD21, CD3, CD4, 
and CD8 were used to identify lymphocyte subsets while CD25, CD62L, Foxp3, 
IFNγ, and IL10 were used to identify T‐cell phenotype. Adipose‐derived MSCs were 
expanded, irradiated (to control proliferation), and incubated with CD4+ T‐cells from 
healthy horses, after which lymphocytes were collected and analyzed via flow cy-
tometry. The percentages of T‐cells and B‐cells in horses with ERU were similar 
to normal horses. However, CD4+ T‐cells from horses with ERU expressed higher 
amounts of IFNγ indicating a pro‐inflammatory Th1 phenotype. When co‐incubated 
with MSCs, activated CD4+ T‐cells reduced expression of CD25, CD62L, Foxp3, 
and IFNγ. MSCs had a lesser ability to decrease activation when cell‐cell contact or 
prostaglandin signaling was blocked. MSCs continue to show promise as a treatment 
for ERU as they decreased the CD4+ T‐cell activation phenotype through a combina-
tion of cell‐cell contact and prostaglandin signaling.
K E Y W O R D S
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1 |  INTRODUCTION
Equine recurrent uveitis (ERU), commonly known as moon 
blindness, is a devastating immune‐mediated disease that 
affects between 2% and 25% of horses, with 1%‐2% of 
American horses showing enough clinical signs to threaten 
vision.1-4 ERU is characterized by recurring flare‐ups of in-
traocular inflammation or low levels of persistent inflamma-
tion, predominantly of the iris, ciliary body, and choroid.5 
Acute symptoms of ERU include miosis, lowered intraocu-
lar pressure, aqueous flare, and iris adhesions, while chronic 
ERU can lead to cataracts, glaucoma, and blindness.5 Three 
clinical forms of ERU have been described, with classic 
ERU being the most common, insidious ERU being char-
acterized by constant and subtle intraocular inflammation, 
and posterior ERU being seen with inflammation mostly 
in the posterior segment of the eye.6 Current treatments for 
ERU, including anti‐inflammatories and immunosuppressive 
drugs, are not curative and only slow the progression of the 
ocular inflammation,7 with approximately 56% of horses af-
fected with ERU eventually becoming blind.4,8 Euthanasia 
or change of ownership are commonly seen as sequelae to 
horses with chronic ERU, and over 60% of ERU horses are 
not able to return to their previous role as a working horse.9 
As a recurring uveitis targeting retinal proteins, ERU serves 
as the only naturally occurring model for human uveitis.10-13
Equine recurrent uveitis symptoms are primarily the re-
sult of T‐cell activation (specifically Th1 and Th17 cells) 
causing destruction of the uveal tract of the eye.14-16 In 
horses, the pro‐inflammatory Th1 subset can be identified by 
cells expressing both interferon gamma (IFNγ) and FoxP3, 
17 while the Th17 subset is associated with markers interleu-
kin (IL)‐6, IL‐17, and IL‐23.18 Naturally occurring T regu-
latory cells (Tregs) express CD25 as well as CD4 or CD8, 
though activated, natural Tregs may also express FoxP3 and 
IL‐10.17,19 Histologically, ERU lesions are CD4+ predomi-
nant with lower percentages of CD8+ T‐cells and increased 
transcription of interleukin IL‐2 and IFNγ, supportive of Th1 
inflammation.16,18,20 Additionally, inflammation in the eye 
has strong immunoreactivity for Th17 cells (IL‐6, IL‐17, and 
IL‐23), suggesting these cells play a role in ERU pathogene-
sis.14,15,18 Eyes affected with ERU have significantly higher 
levels of the anti‐inflammatory cytokine IL‐10, indicating 
that IL‐10 may play an important role in ERU.21
While the ERU inflammatory lesion is well characterized 
in the uveal tract and in the aqueous humor, there is a need 
to identify more accessible blood biomarkers to help iden-
tify horses and monitor response to therapeutic interventions. 
Models of ocular autoimmune diseases are characterized 
by activated CD4+ T‐cells in both peripheral blood and in 
infiltrating leukocytes.11,22 In the induced equine model of 
ERU specifically, autoreactive peripheral blood lymphocytes 
traffic in blood and migrate to the eye.11,23 Lymphocytes 
dominate the leukocyte infiltrate in ERU, and the majority 
of these cells are CD4+ T‐cells.12 In proteomic studies, these 
autoreactive lymphocytes express proteins associated with 
cell migration and immunity,11,15 including formin‐like 1, 
which is highly expressed in peripheral blood lymphocytes.23 
This CD4+ T‐cell membrane protein, involved in phagocy-
tosis, cell adhesion, and cell migration, was found to be of 
significantly higher abundance in the proteome of horses 
with ERU.23 Although activated T‐cells in peripheral blood 
may not perfectly reflect the ocular infiltrate, changes in pe-
ripheral blood leukocytes may provide readily accessible data 
on immune cell activation, disease dynamics and remission, 
and therapeutic efficacy of novel immunotherapies. The per-
centages of blood CD4+ T‐cells, CD8+ T‐cells, and B‐cells 
(CD21+) and the distribution of Th1 and Tregs in horses with 
ERU is currently unknown.
Most of our current knowledge of ocular inflammation, 
especially in the serum, focuses on pro‐inflammatory cy-
tokines such as IFNγ, IL‐1a, IL‐6, and IL‐17.21 However, 
autoimmune diseases, such as ERU, can also result from a 
lack of immunosuppression (ie, an absence of Tregs]).24,25 
Tregs, also known as suppressor T‐cells, are a subpopulation 
of T‐cells which modulate the immune system and abrogate 
autoimmune disease in part via suppressing proliferation of 
effector Th1 and Th17 cells. There is a developing body of in 
vivo and in vitro data in veterinary medicine that shows that 
mesenchymal stem cells (MSCs) used in immune‐mediated 
and inflammatory diseases can induce a switch from pro‐in-
flammatory T‐cell subsets (Th1/Th17) to regulatory suppres-
sive T‐cell subsets (Tregs).26-29
Mesenchymal stem cells are multipotent stromal cells 
with powerful pro‐regenerative and anti‐inflammatory prop-
erties.30 MSCs have been isolated from a number of tissues 
and expanded ex vivo can be used as a therapeutic agent.31 
Equine MSCs derived from bone marrow, adipose, umbilical 
cord blood and umbilical cord tissue have all been shown to 
reduce activated T‐cell proliferation in vitro though adipose‐
derived MSCs may be easier to access and grow.32 MSC’s 
regenerative ability is attributed in part to their ability to 
modulate both innate and adaptive immune responses,33,34 
as they produce a variety of immunomodulating factors in-
cluding IL‐6, prostaglandin E2 (PGE2) and nitric oxide.32,35 
These secreted factors inhibit activated T‐cell proliferation, 
decrease pro‐inflammatory cytokine secretion and increase 
Treg numbers.27,34,35 Human MSCs decrease activated T‐
cell proliferation as well as decrease expression of IFNγ and 
CD25.36 In rodent models of induced autoimmune uveitis, 
MSCs are immunosuppressive. They downregulate activated 
T‐cells, increase number and function of Tregs and reduce 
inflammation for an extended amount of time.37,38
The goals of this study were to determine blood immune 
cell phenotype in horses with ERU and to then determine 
whether MSCs could alter this phenotype in vitro. We 
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hypothesized that horses with ERU would have a pro‐in-
flammatory immune cell phenotype, showing Th1 activa-
tion, and that MSCs would decrease these T‐cell subsets in 
vitro, shifting toward Treg subsets. We found that horses 
with ERU show an activated CD4+ T‐cell phenotype and 
that MSCs were able to reduce CD4+ T‐cell activation in 
vitro.
2 |  MATERIALS AND METHODS
2.1 | Horses
Blood from 10 clinically healthy horses was collected for im-
mune cell phenotyping. These horses were determined to be 
healthy based on a complete blood count (CBC), biochemi-
cal profile, physical examination and ocular examination. 
All horses had a clear medical history for any inflammatory 
disease or medical intervention besides vaccines for at least 
6 months. Horses over the age of 20 were excluded due to 
age‐associated alterations in CD4+ FoxP3+ cells.17
Blood from seven ERU horses was collected for immune 
cell phenotyping. These horses had a history of ERU (includ-
ing anterior or posterior synechia, cataract, glaucoma, degen-
erative/discolored vitreous, and/or peripapillary chorioretinal 
scarring) and an active uveitis flare. Horses were not on sys-
temic or topical steroidal or nonsteroidal therapies at the time 
of blood collection.
Healthy horses included the following: Hanoverians (2), 
American Quarter Horses (2), Czech warmblood (1), Belgian 
warmblood (1), Thoroughbred (1), Irish sport horse (1), 
Standardbred (1), and one of unknown breed. Both geldings 
(6) and mares (4) were represented, with ages ranging from 
9 to 20. ERU horses included the following: Appaloosas (5), 
Dutch warmbloods (1), and one of unknown breed. Mares 
(2), geldings (4), and a stallion were represented, and ages 
ranged from 4 to 20.
Blood was also collected from healthy horses under the 
age of 15 housed at the Center for Equine Health (CEH), UC 
Davis, CA for use in in vitro studies. All protocols were ap-
proved by the Institutional Animal Care and Use Committee 
and the Clinical Trials Review Board at the University of 
California, Davis.
2.2 | Immune cell characterization
Equine whole blood was collected via jugular venipunc-
ture into sodium heparin vacutainers (BD Biosciences). 
Peripheral blood mononuclear cells (PBMCs) were iso-
lated using a Ficoll gradient and resuspended in lympho-
cyte stimulation media, consisting of RPMI 1640 media 
(Gibco, Invitrogen) with 10% fetal bovine serum (FBS; 
Atlanta Biologicals), 1% GlutaMax (Gibco), 1  mmol/L 
Na Pyruvate (Gibco), 75  µg/mL gentamicin (Gibco), 
2  mmol/L 4‐(2‐hydroxyethyl)‐1‐piperazineethanesulfonic 
acid (HEPES) buffer (Gibco), 1 µL/mL minimum essential 
medium nonessential amino acids (MEM NEAA; Gibco), 
and 55 µmol/L b‐mercaptoethanol (Bio‐Rad Laboratories).32 
PBMCs were variably labeled with antibodies that cross‐
react with equine leukocytes. Specifically, B‐cells were la-
beled with CD21 (BD Pharmingen, Clone B‐ly4),39 T‐cells 
with CD3 (Dr Jeffrey Stott, UCD, School of Veterinary 
Medicine, Clone UC F6G),40 CD4 (Monoclonal Antibody 
Center, Washington State University, Pullman, WA, Clone 
HB61A),41 CD8 (Dr Jeffrey Stott, Clone CVS8),39 CD25 
(R&D Systems, polyclonal anti‐human CD25/IL‐2R alpha 
Clone AF‐223‐NA),17 and CD62L (MyBioSource, Clone 
LAM1‐116). After surface markers were labeled, cells were 
labeled with Foxp3 antibody (eBioscience, clone FJK‐16s,17 
using the manufacturer's fixation/ permeabilization buffer. 
Cells to be labeled for intracellular cytokines were stimu-
lated with 25  ng/mL phorbol 12‐myristate 13‐acetate 
(PMA), 1 µmol/L ionomycin, and 10 µg/mL Brefeldin A for 
3 hours to activate equine T‐cells.17,42 These cells were fixed 
with 2% paraformaldehyde and washed/permeabilized with 
a buffer containing 0.5% BSA and 0.1% saponin (Wagner), 
and then labeled for IFNγ (Bio‐Rad, Clone CC302)42 and 
IL‐10 (Wagner Laboratories, Cornell University, Ithaca, 
NY, Clone 165‐2).42 Cells were resuspended in flow buffer 
(Dulbecco's phosphate‐buffered saline (DPBS), Gibco) with 
2% FBS and 2 mmol/L EDTA (Sigma‐Aldrich) and read on 
a Cytomics FC500 flow cytometer (Beckman Coulter). Flow 
cytometry data were analyzed using FlowJo software (Tree 
Star Inc). The percentage of CD25+, CD62L+, FoxP3+, 
IFNγ+, and IL‐10+ cells were gated from CD4+ or CD8+ 
cells.
2.3 | Mesenchymal stem cells and CD4+ T‐
cell co‐incubations
2.3.1 | Mesenchymal stem cells 
collection and culture
Seven cryopreserved primary adipose‐derived MSC lines 
were used in this study. MSCs were obtained from either 
healthy horses housed at the CEH or from the Regenerative 
Medicine Laboratory (RML) at UC Davis. All samples were 
obtained from adult horses following approved animal care 
and use protocols. All MSC lines were phenotyped by our 
laboratory prior to this study.32,43 MSCs are CD90, CD44, 
MHC I, and CD29 positive and MHC II and F6B (pan leu-
kocyte) negative. For experimental use, cells were thawed 
in a 37°C water bath, centrifuged (100x  g, 10  minutes), 
and plated into a tissue culture flask in media (Dulbecco's 
Modified Eagle's Medium (DMEM), Gibco] with 10% FBS 
and 1% penicillin‐streptomycin (Gibco)). Cells were cul-
tured at 37°C in 5% CO2. When cells were ~70% confluent, 
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they were trypsinized using 0.05% Trypsin/EDTA (Gibco) 
and resuspended in media to prepare for co‐incubation 
studies. All MSCs were between passages 2 and 4 for 
experimentation.
2.3.2 | Irradiation
To prevent MSC proliferation, cells were irradiated at 10 Gy 
(Varian 2100C linear accelerator, Varian Medical Systems). 
After irradiation, MSCs were washed (100x g, 10 minutes), 
resuspended in media, and kept on ice until co‐incubation 
plating.
2.3.3 | CD4 + T‐cell isolation
Peripheral blood mononuclear cells were isolated from equine 
whole blood as described above and resuspended in DPBS. 
Cells were filtered through a 35  µm cell strainer cap (BD 
Biosciences), washed (400x  g, 5  minutes), and resuspended 
in MACs buffer (DPBS, 0.5% bovine serum albumin (Gibco), 
2  mmol/L EDTA). Cells were labeled for CD4 followed by 
anti‐mouse IgG Microbeads (Miltenyi Biotec). Cells were run 
through a MACS LS separation column (Miltenyi Biotec) per 
manufacturer's recommendation, and purity of CD4+ T‐cells 
after this column was confirmed by flow cytometry to be ≥95%. 
Isolated CD4+ T‐cells were resuspended in media.
2.3.4 | Co‐incubation setup
CD4+ T‐cells were plated alone or at a ratio of 5:1 with MSCs 
in 12‐well plates (Falcon, Corning, Inc, Corning, NY) with or 
without activation (0.5% phytohemagglutinin [PHA]). Plates 
were incubated at 37°C, 5% CO2 for 4 days. For some experi-
ments, MSCs were separated from CD4+ T‐cells using transwell 
inserts (Corning). For other experiments, 1% indomethacin 
(5 mmol/L in DMSO) was added to the wells to block pros-
taglandin signaling. After 4 days, cells were collected, labeled 
for CD4, CD25, CD62L, FoxP3, IFNγ, and IL‐10, and read 
on a flow cytometer as previously described. Data were ana-
lyzed using FlowJo flow cytometry software. The percentage of 
CD25+, CD62L+, FoxP3+, IFNγ+, and IL‐10+ cells were gated 
from CD4+ cells.
2.4 | Data analysis
The Grubbs’ test was used to detect outliers, although all out-
liers were included in additional tests and depicted in figures. 
Normality was determined using the Shapiro‐Wilk test. For 
nonparametric results, statistical significance was determined 
using the Mann‐Whitney test. For parametric results compar-
ing two outcomes, data were analyzed by paired t tests. For 
parametric results comparing more than two conditions, the 
ANOVA was used (GraphPad InStat version 3.06). For all 
results, P < .05 was considered statistically significant.
3 |  RESULTS
3.1 | Healthy horses and horses with ERU 
have similar percentages of blood CD3+ T 
lymphocytes (CD4+ and CD8+subsets) and B 
lymphocytes
Normal horses and ERU horses had similar percentages of 
circulating T‐cells (CD3+), CD3+CD4+ cells (T helper cells), 
CD3+CD8+ cells (cytotoxic T‐cells), and CD21+ cells (B‐
cells) (Table 1). There was no significant difference between 
the percentages of these cell types for the horse groups.
3.2 | Equine recurrent uveitis horses have 
an activated CD4+ blood T‐cell phenotype
CD4+ T‐cells from ERU horses expressed significantly higher 
levels of IFNγ (P = .01, Figure 1A) than control horses, and 
showed a trend toward expressing lower levels of IL‐10 
(P = .07, Figure 1B), indicative of a shift toward a Th1 acti-
vation phenotype. There was no difference in the percentage 
of circulating in CD4+ T‐cells that were positive for FoxP3 or 
CD25, normally associated with CD4 Tregs, between ERU 
horses and control horses (P = .32, Figure 1C, P = .2, Figure 
1D, respectively). The mean fluorescence of CD25 on CD4+ 
Marker Horse group Cell type Ranges (%) Average(%) P Value
CD3 Normal T‐cell 39.2‐73.8 59.8 .95
ERU 15.2‐79.7 55.7
CD4 Normal T helper cell 69.0‐85.3 76.8 .18
ERU 63.8‐74.0 72.4
CD8 Normal Cytotoxic T‐cells 6.4‐27.0 15.3 .30
ERU 13.1‐26.3 20.0
CD21 Normal B‐cells 2.8‐19.9 11.8 .27
ERU 3.6‐12.9 8.7
T A B L E  1  Normal horse and ERU 
horse lymphocyte ranges
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T‐cells was also evaluated (CD25hi) and not noted to be dif-
ferent between control and ERU horses. Lymphocytes from 
horses with ERU had significantly increased expression of 
CD62L (P < .01, Figure 1E), associated with a naïve or cen-
tral memory phenotype, compared to healthy horses.
3.3 | CD8+ T‐cells from ERU horses have 
increased expression of CD62L but otherwise 
do not reflect alterations noted in CD4+ cells
CD8+ T‐cells from ERU horses did not have increased IFNγ 
compared to healthy horses (P  =  .41, Figure 2A) and had 
slightly lower levels of IL‐10 (P  =  .09, Figure 2B). ERU 
horses did have slightly higher levels of FoxP3 (P  =  .06, 
Figure 2C) than healthy horses; however, this was not signifi-
cant. The percentage of CD25+ CD8+ T‐cells was not altered 
in ERU horses (P = .89, Figure 2D). Taken together, there 
was no distinct pattern indicating CD8+ T‐cell activation or 
Tregs in ERU horses. Similar to CD4+ T‐cells, CD8+ T‐cells 
had significantly increased CD62L expression (P  =  .02, 
Figure 2E).
3.4 | Mesenchymal stem cells decrease CD4+ 
T‐cell activation phenotype
Phytohemagglutinin activation of equine CD4+ T‐cells re-
sulted in increased intracellular accumulation of IFNγ, IL‐10, 
and FoxP3 (P < .01, Figure 3A, P < .01, Figure 3B, P < .01, 
Figure 3C) and increased surface expression of CD25 and 
CD62L (P < .01, Figure 3D, P = .05, Figure 3E). MSCs sig-
nificantly decreased measured markers of T‐cell activation 
including decreased intracellular IFNγ (P < .01, Figure 3A), 
intracellular FoxP3 (P < .01, Figure 3C), and surface CD25 
(P = .01, Figure 3D). MSCs were able to downregulate CD25 
even in the absence of activation (P = .01, Figure 3D). MSCs 
did not change CD4+ T‐cell expression of IL‐10, regardless 
F I G U R E  1  CD4+ T‐cells show 
increased levels of IFNγ expressing CD4+ 
T‐cells. (A‐C) ERU horses and control 
horses express similar levels of CD25+, 
IL10+ and FoxP3+ CD4+ T‐cells. (D‐E) 
ERU have significantly higher levels of 
IFNγ+ CD4+ T‐cells and CD62L+ CD4+ 
T‐cells. Data are shown as box and whisker 
plots with a mean value shown as the middle 
bar and the range being from minimum 
to maximum value. Open dots represent 
outliers. *P < .05
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of activation (P = .14, Figure 3C). MSCs were also able to 
decrease surface CD62L (P =  .02, Figure 3D) in activated 
CD4+ T‐cells.
3.5 | Soluble mediators produced by MSCs 
reduce CD4+ T‐cell activation whereas cell‐cell 
contact is needed for MSCs to induce CD4+ 
effector/effector memory cells
Mesenchymal stem cells reduced activated CD4+ T‐cell ac-
tivation indicated by decreased expression of IFNγ (P = .03 
Figure 4A) and FoxP3 (P  =  .01, Figure 4B) with or with-
out cell‐cell contact indicating a soluble mediator was re-
sponsible for these changes. However for another indicator 
of T‐cell activation CD25 expression MSCs relied on direct 
CD4+ T‐cell‐MSC interaction to reduce CD25 expression 
(as CD25 expression was largely restored when MSCs were 
separated from T‐cells by a transwell) (P = .09, Figure 4C). 
Similarly the induction of CD4+ effector/effector memory 
cells (CD62L‐) by MSCs requires cell‐cell contact as there 
was no difference in CD62L levels between activated CD4+ 
T‐cells and CD4+ T‐cells separated from MSCs by a tran-
swell (P = .57, Figure 4D).
3.6 | Prostaglandin is required for MSC 
reduction of CD25 and IFNγ expression in 
activated CD4 + T‐cells
When prostaglandin signaling was blocked in the co‐incuba-
tions, lymphocyte secretion of IFNγ was restored (P = .67, 
Figure 5A). However, MSCs were still able to reduce intra-
cellular FoxP3 expression (P =  .01, Figure 5B) suggesting 
that PGE2 is not the soluble mediator responsible for reduc-
tion of FoxP3. In the absence of PGE2, MSCs were unable to 
F I G U R E  2  CD8+ T‐cells showed 
similar phenotypes between normal and 
ERU horses. A‐D, ERU horses and control 
horses had similar levels of expression of 
IFNγ, IL10, FoxP3, and CD25. E, ERU 
horses had higher levels of CD8 + CD62L+ 
cells than control horses. Data are shown 
as box and whisker plots with a mean value 
shown as the middle bar and the range being 
from minimum to maximum value. Open 
dots represent outliers. *P < .05
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decrease CD25 expression suggesting that PGE2 is partially 
responsible for this MSC‐mediated decrease in lymphocyte 
activation. (P = .14, Figure 5C). MSCs were able to reduce 
CD62L (P = .05, Figure 5D) expression on activated CD4+ 
T‐cells both with and without prostaglandin signaling.
4 |  DISCUSSION
Equine recurrent uveitis is an inflammatory, autoimmune 
disease with characteristics similar to human uveitis.13,21 
Previous studies have shown that T lymphocytes, espe-
cially CD4+ T‐cells, are the predominant inflammatory cell 
present in ERU tissues.18,23 Our data, however, suggest that 
the percentage of CD3+, CD8+, and CD4+ lymphocytes 
in blood are similar between normal horses and horses 
with ERU. Our work also showed an increase in activated 
CD4+ T‐cells with increased IFNγ expression, which is 
similar to another study that found that horses with marked 
ocular inflammation have higher serum levels of IFNγ.21 
Overall, we saw a shift toward Th1 inflammation in horses 
with ERU, as CD4+ T‐cells expressed increased levels of 
IFNγ, and some horses showed a concurrent expression of 
IFNγ from CD8+ T‐cells. ERU horses showed no changes 
in CD4+ T‐cell expression of FoxP3, IL‐10, or CD25 or 
CD8+ T‐cell expression of IL‐10 or CD25. These data sug-
gest that ERU horses do not have specific patterns of altera-
tions in circulating markers of Tregs, though examination 
of additional ERU horses would help to confirm this lack 
of alteration. Differences in the subclinical type of ERU 
and genetic background may also contribute to patterns in 
T‐cells that should be examined.
F I G U R E  3  CD4+ T‐cells have 
a lowered activation phenotype after 
four day co‐incubation with MSCs. (A) 
CD4+ T‐cells had lowered expression of 
CD25 when co‐incubated with MSCs, 
both with and without activation by 
PHA. (B) Intracellular IL‐10 showed no 
change based on co‐incubated with MSCs. 
Intracellular FoxP3 (C), intracellular IFNγ 
(D), and surface CD62L (E) expression 
was lowered in activated CD4+ T‐cells 
that were co‐incubated with MSCs. Data 
are presented as mean ± standard error of 
the mean. *P < .05; CD4, CD4+ T‐cells; 
MSC, mesenchymal stem cells; PHA, 
phytohemagglutinin
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Equine recurrent uveitis horses may have a shift toward 
central memory cells, indicated by both circulating CD4+ 
and CD8+ T‐cells having increased CD62L (aka L selec-
tin) expression. CD62L is a lymphocyte adhesion molecule 
that plays an important role in lymphocyte‐endothelial cell 
adhesion and lymphocyte homing. Central memory T lym-
phocytes have encountered antigen and express CD62L to 
localize in secondary lymphoid organs.
A number of studies have looked at the immunomodula-
tory effects of MSCs in horses, showing that equine MSCs, 
much like other species, can inhibit activated T‐cell prolif-
eration and decrease TNFα and IFNγ production27,32 in part 
through the secretion of PGE2. Our study has expanded on 
these findings and demonstrated that equine MSCs also 
decrease CD4+ T‐cells expression of CD25 (IL‐2 recep-
tor), through cell‐cell contact. Human MSCs also decrease 
CD25 through MSC‐lymphocyte contact via PD‐L1/ PD‐1.36 
Equine adipose‐derived MSCs, like we used in this study, in-
duce lymphocyte apoptosis, which may also be done through 
PD‐L1/PD‐1 pathway.27 Equine MSC downregulation of 
CD25 on CD4+ T‐cells is also facilitated by MSC secretion 
of PGE2. These data confirmed our previous findings that 
equine MSCs decrease protein secretion of IFNγ (as mea-
sured by supernatant in co‐culture assays),27 by demonstrat-
ing the specific reduction of intracellular IFNγ accumulation 
in CD4+ T‐cells mediated via PGE2 signaling.
FoxP3 is a cytokine known to play many roles and is 
generally associated with Treg function,17 but has also re-
cently been associated with T‐cell activation in humans and 
horses.44,45 Furthermore, in horses, the induced expression of 
FoxP3 by activated T‐cells was associated with a regulatory 
cytokine profile. Similar to Cavatorta et al, our data confirm 
that FoxP3 is regulated similarly in horses and humans and 
is an inherent component of T‐cell activation and prolifera-
tion. Our data demonstrate that equine MSCs decrease FoxP3 
expression by activated, proliferating CD4+ T‐cells through 
a soluble mediator.45 This mediator was not PGE2 in our as-
says, and equine adipose‐derived MSCs do not produce NO 
F I G U R E  4  Differences between 
contact and no contact co‐incubations of 
activated CD4+ T‐cells with MSCs. Co‐
incubation with MSCs induced a reduction 
in expression of intracellular IFNγ (A) and 
FoxP3 (B) both with contact and without 
contact. (C) While co‐incubation with 
MSCs reduced activated CD4 + T‐cells 
expression of CD25 with contact, without 
contact, no reduction of CD25 was seen. (D) 
Co‐incubations with MSCs without contact 
did not reduce CD4+ T‐cell expression of 
CD62L. *P < .05
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or IDO,32 as such FoxP3 reduction may be mediated through 
TGFβ or IL‐6. Cavatorta et al also determined that although 
FoxP3+ T‐cells were capable of producing IFNγ, they were 
more likely to produce IL‐10 and less likely to produce IFNγ 
than equivalent FoxP3− cells. This may explain why T‐cell 
activation in our hands increased IFNγ, FoxP3, and IL‐10. 
The concurrent reduction in IFNγ and FoxP3 by equine 
MSCs provide some evidence that MSCs could be useful to 
decrease CD4+ T‐cell activation, and induce tolerance, in 
horses with diseases such as ERU that are characterized by 
T‐cell activation.
CD62L was used in this study to look at T‐cell activa-
tion, effector memory, and central memory/naive lymphocyte 
subsets. Interestingly, horses with ERU have higher percent-
ages CD62L+ T‐cells compared to healthy horses suggesting 
increased numbers of central memory/naive cells. In vitro, 
equine MSCs induced a switch to effector memory cells as 
seen by decreased CD62L expression on activated CD4+ T‐
cells after direct cell‐cell contact with MSCs. Ligand pairs 
known to be important in MSC‐lymphocyte adhesion and sig-
naling include PD‐L1/PD‐1, ICAM‐1/LFA‐1, and VCAM‐1/
VLA‐4.36,46,47 Our data do not agree with data from a murine 
study that demonstrated that CD62L was maintained/upreg-
ulated after MSC/lymphocyte co‐incubation48; however, the 
induction of effector memory cells has been reported in a 
human study after MSC infusion.49 ERU horses have high 
numbers of CD62L+ CD4+ and CD8+ T‐cells and equine 
MSCs in vitro can cleave CD62L resulting in a shift to effec-
tor memory cells. To confirm this finding, evaluating CD62L 
levels in additional ERU affected horses and controls are 
warranted.
Horses with ERU have a shift toward a Th1 inflammatory 
phenotype (CD4+ IFNγ+) with increased numbers of central 
memory/naïve CD4 and CD8 T‐cells. In vitro, equine MSCs 
reduce IFNγ expression, decrease T‐cell activation (and pro-
liferation) in general (including decreased FoxP3 and CD25), 
and increase effector and effector memory cells via cleaving 
CD62L. Like other MSCs, equine MSCs appear to rely on 
both soluble mediators and cell‐cell contact for their immu-
nomodulatory properties. These data suggest that ERU may 
be an appropriate target for MSC therapy (along with other 
equine diseases characterized by this immune phenotype). In 
F I G U R E  5  Differences between 
contact and prostaglandin blocked co‐
incubations of activated CD4+ T‐cells with 
MSCs. A, With contact, co‐incubations with 
MSCs reduced CD4+ T‐cell expression 
of IFNγ. However, without prostaglandin 
signaling, IFNγ expression was not reduced. 
B, Expression of intracellular FoxP3 was 
reduced in the presence of MSCs both with 
and without prostaglandin signaling. C, 
While co‐incubations with MSCs reduced 
CD25 expression in contact co‐incubations, 
without prostaglandin signaling, no 
reduction of CD25 was seen. D, CD62L 
expression by activated CD4+ T‐cells was 
reduced in co‐incubations both with and 
without prostaglandin signaling. *P < .05; 
PGE, prostaglandin
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addition, the data highlight some objective blood biomark-
ers that could be monitored in ERU horses prior to and post‐
MSC transfusion.
Future clinical applications for MSCs in treating ERU ap-
pear to be promising. Our laboratory has consistently found 
the intravenous (IV) administration of MSCs to be safe.29 
We have treated 3 ERU horses with MSCs IV, and the horses 
did very well after these infusions. However, it is unknown 
if these MSCs will disproportionately reach the eye or affect 
ocular inflammation. Intravitreal injections in horses have 
been attempted, but have been associated with significant ad-
verse events and are not recommended (unpublished data). 
Recent studies have had success with subconjunctival MSC 
injections, which may be a promising method for treatment 
of ERU.50 Additional prospective studies will be needed to 
assess the effect of MSC administration on ocular inflamma-
tion in vivo.
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